(Q37820669)

23 August 2017

1 reference

title

Towards a Chlamydia trachomatis vaccine: how close are we? (English)

1 reference

23 August 2017

main subject

Chlamydia trachomatis

0 references

Charles W Armitage

2

0 references

author name string

Melanie Cochrane

series ordinal

1

1 reference

23 August 2017

Connor P O'Meara

series ordinal

3

1 reference

23 August 2017

Kenneth W Beagley

series ordinal

4

1 reference

23 August 2017

publication date

1 December 2010

1 reference

23 August 2017

number of pages

24

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

23 August 2017

volume

5

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1833-1856

1 reference

Clinical practice. Genital chlamydial infections

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Presence of the major outer-membrane protein of Chlamydia trachomatis in patients with chronic salpingitis and salpingitis isthmica nodosa with tubal occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Male genital tract chlamydial infection: implications for pathology and infertility.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Phagocytosis of spermatozoa and leucocytes by epithelial cells of the genital tract in infertile men infected with Chlamydia trachomatis and mycoplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Acrosome reaction in Chlamydia-positive and negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Sperm DNA fragmentation in infertile men with genitourinary infection by Chlamydia trachomatis and Mycoplasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydial infection of immune cells: altered function and implications for disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The obligate intracellular bacterium Chlamydia trachomatis is auxotrophic for three of the four ribonucleoside triphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Mechanisms of Chlamydia trachomatis entry into nonphagocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Origins and functions of the chlamydial inclusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The radical site in chlamydial ribonucleotide reductase defines a new R2 subclass

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Inhibition of staurosporine-induced activation of the proapoptotic multidomain Bcl-2 proteins Bax and Bak by three invasive chlamydial species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor-? in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia trachomatis persistence in vitro: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Aberrant chlamydial developmental forms in the gastrointestinal tract of pigs spontaneously and experimentally infected with Chlamydia suis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Mechanisms of host cell exit by the intracellular bacterium Chlamydia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia trachomatis serovar E isolates from patients with different clinical manifestations have similar courses of infection in a murine model: host factors as major determinants of C trachomatis mediated pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Characterization of Chlamydial Genital Infection Resulting from Sexual Transmission from Male to Female Guinea Pigs and Determination of Infectious Dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Modeling infectious disease in mice: co-adaptation and the role of host-specific IFNgamma responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Immunity to murine chlamydial genital infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydial IFN-gamma immune evasion is linked to host infection tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Strain and virulence diversity in the mouse pathogen Chlamydia muridarum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia muridarum evades growth restriction by the IFN-gamma-inducible host resistance factor Irgb10.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The cellular paradigm of chlamydial pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Pathogenesis of genital tract disease due to Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Interleukin-1 is the initiator of Fallopian tube destruction during Chlamydia trachomatis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A link between neutrophils and chronic disease manifestations of Chlamydia muridarum urogenital infection of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Molecular mimicry and horror autotoxicus: do chlamydial infections elicit autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Mycobacterium bovisBCG-Specific Th17 Cells Confer Partial Protection againstMycobacterium tuberculosisInfection in the Absence of Gamma Interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Interleukin-17: an emerging role in lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The arrested immunity hypothesis and the epidemiology of chlamydia control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Vaccination with temperature-sensitive mutant of Chlamydia psittaci against enzootic abortion of ewes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Use of a live chlamydial vaccine to prevent ovine enzootic abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Vaccination against chlamydial infections of man and animals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia vaccine candidates and tools for chlamydial antigen discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Characterization of a secreted Chlamydia protease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia pneumoniae major outer membrane protein is a surface-exposed antigen that elicits antibodies primarily directed against conformation-dependent determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Profiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Discovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

An Inclusion Membrane Protein from Chlamydia trachomatis Enters the MHC Class I Pathway and Stimulates a CD8+ T Cell Response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydial heat shock protein 60--specific T cells in inflamed salpingeal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Expression library immunization confers partial protection against Chlamydia muridarum genital infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydial vaccines--future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia trachomatis infection: host immune responses and potential vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A vault nanoparticle vaccine induces protective mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The chlamydial developmental cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Immunotyping of Chlamydia trachomatis with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Genotyping of urogenital Chlamydia trachomatis in Regional New South Wales, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Cleavage of host keratin 8 by a Chlamydia-secreted protease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Proteomic analysis of Chlamydia pneumoniae-infected HL cells reveals extensive degradation of cytoskeletal proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Human antibody responses to a Chlamydia-secreted protease factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Alternative routes of mucosal immunization in large animals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Nanotechnology in vaccine development: a step forward

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms (Review)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Targeted vaccine adjuvants based on modified cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

New strategies for combination vaccines based on the extended recombinant bacterial ghost system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Mucosal vaccines: the promise and the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Measuring serum antibody to human papillomavirus following infection or vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Critical role for interleukin-1beta (IL-1beta) during Chlamydia muridarum genital infection and bacterial replication-independent secretion of IL-1beta in mouse macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Mice deficient in MyD88 Develop a Th2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Poly-immunoglobulin receptor-mediated transport of IgA into the male genital tract is important for clearance of Chlamydia muridarum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.148

21 January 2018

Identifiers

DOI

10.2217/FMB.10.148

1 reference

23 August 2017

1 reference